This year could see a transformation in the Japanese pharma market, according to a new report, with strong growth stemming from increased use of generics, biosimilars and stronger links with the global industry.
Sandoz, a Novartis division and the global leader in biosimilars, announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.